Pro00019086 - Ultra Circumference Reduction
2017年11月28日 更新者:Alma Lasers Inc.
A Multi-Center Pilot Study to Assess the Safety and Efficacy of the vShape Ultra UltraSpeed Handpiece for Abdomen Circumference Reduction
A Multi-Center Pilot Study to Assess the Safety and Efficacy of the VShape Ultra UltraSpeed Handpiece for Abdomen Circumference Reduction
研究概览
研究类型
介入性
注册 (预期的)
21
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Colorado
-
Greenwood Village、Colorado、美国、80111
- AboutSkin dermatology
-
-
Maryland
-
Glen Burnie、Maryland、美国、21061
- Maryland Plastic Surgery
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- Dr. Brian S. Biesman
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 45年 (成人)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- Signed informed consent to participate in the study.
- Female and male subjects, between 18 and 45 years of age at the time of enrollment.
- Fitzpatrick Skin Type I to VI.
- Fat thickness of at least 1.5 cm in the treated area (measured by calibrated caliper).
- BMI interval: BMI between 20 to 30 (normal to overweight, but not obese).
- If female, not pregnant or lactating, must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
- In addition, negative urine pregnancy test as tested before each treatment and at the last follow-up visit for women with childbearing potential (e.g., not menopausal).
- General good health confirmed by medical history and skin examination of the treated area.
- Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
- Willingness to refrain from a change in diet / exercise / medication regimen for the entire course of the study.
- Willing to have photographs and images taken of the treated areas to be used, de-identified in evaluations, publications and presentations.
Exclusion Criteria:
- History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker / defibrillator, abnormal aortic aneurism.
- Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease.
- Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
- Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
- Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone.
- Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction.
- Previous body contouring procedures in the treatment area within 12 months.
- History of skin disease in the treatment area; known tendency to form keloids or poor wound healing.
- Suffering from significant skin conditions in the treatment areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during treatment course.
- Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions), including depressed scars in the treatment area.
- Very poor skin quality (i.e., severe laxity).
- Abnormal wall diastasis or hernia on physical examination.
- Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months.
- Obesity (BMI above 30)
- Childbirth within the last 12 months or breastfeeding women.
- Any acute or chronic condition which, in the opinion of the Investigator may exclude the candidate / patient from entry into the study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:UltraSpeed Treatment
UltraSpeed ultrasound treatments
|
UltraSpeed ultrasound treatment, a series of four treatments
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Average Circumference Reduction as Measured by Skin Fold and Photography
大体时间:4 Treatments over 4 Weeks
|
Skin fold measure utilizes caliper and photography utilizes Galaxy medical camera with extrapolation of measuring dot.
Last measurement taken 14 days after final treatment.
|
4 Treatments over 4 Weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年10月1日
初级完成 (实际的)
2017年11月1日
研究完成 (预期的)
2017年11月1日
研究注册日期
首次提交
2016年10月13日
首先提交符合 QC 标准的
2017年4月11日
首次发布 (实际的)
2017年4月14日
研究记录更新
最后更新发布 (实际的)
2017年11月30日
上次提交的符合 QC 标准的更新
2017年11月28日
最后验证
2017年4月1日
更多信息
与本研究相关的术语
其他研究编号
- AlmaLasersInc
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Alma vShape Ultra的临床试验
-
University of WashingtonNational Institute on Minority Health and Health Disparities (NIMHD)完全的
-
Dr. Filippo MurinaOpera CRO, a TIGERMED Group Company尚未招聘
-
Dr. Filippo MurinaOpera CRO, a TIGERMED Group Company尚未招聘
-
University of WashingtonNational Institute on Minority Health and Health Disparities (NIMHD)撤销
-
Sheba Medical CenterKaplan Medical Center; The Baruch Padeh Medical Center, Poriya未知
-
Edwards Lifesciences招聘中